Published in Medical Letter on the CDC and FDA, August 26th, 2007
Net revenues were $16.4 million in the second quarter of 2007 compared to $3.8 million in the second quarter of 2006, reflecting significantly higher net product sales following the July 2006 launch of Oracea(R), the only FDA-approved systemic treatment of rosacea. Net sales of Oracea were $13.1 million in the second quarter of 2007.
Net loss allocable to common stockholders for the second quarter of 2007 was $4.8 million, or $0.23 per basic and diluted share, compared to a net loss allocable to common stockholders of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.